| Identification | Back Directory | [Name]
SB 223412 | [CAS]
174636-32-9 | [Synonyms]
CS-1123
SB 223412
Talnetant (SB 223412)
SB-223412; SB223412; SB 223412
3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
(S)-N-(1-Phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
3-Hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide
4-Quinolinecarboxamide, 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]-
(-)-3-Hydroxy-2-phenyl-N-[1(S)-phenylpropyl]quinoline-4-carboxamide
(-)-(S)-N-(alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxaMide
Talnetant/(S)-3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
TALNETANT//SB223412//3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxaMide | [Molecular Formula]
C25H22N2O2 | [MDL Number]
MFCD00944075 | [MOL File]
174636-32-9.mol | [Molecular Weight]
382.45 |
| Chemical Properties | Back Directory | [Melting point ]
125.1-126.2℃ | [Boiling point ]
580.4±50.0 °C(Predicted) | [density ]
1.212±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO: soluble25mg/mL, clear | [form ]
powder | [pka]
6.70±0.50(Predicted) | [color ]
white to beige | [Optical Rotation]
[α]/D -25 to -31°, c = 0.5 in methanol | [InChI]
1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29)/t20-/m0/s1 | [InChIKey]
BIAVGWDGIJKWRM-FQEVSTJZSA-N | [SMILES]
OC(C(C(N[C@H](C1=CC=CC=C1)CC)=O)=C(C=CC=C2)C2=N3)=C3C4=CC=CC=C4 |
| Safety Data | Back Directory | [Hazard Codes ]
T | [Risk Statements ]
25 | [Safety Statements ]
45 | [RIDADR ]
UN 2811 6.1 / PGIII | [WGK Germany ]
WGK 3 | [Storage Class]
6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | [Hazard Classifications]
Acute Tox. 3 Oral |
| Hazard Information | Back Directory | [Description]
Talnetant is an antagonist of the neurokinin-3 (NK3) receptor (Ki = 1 nM). It is selective for NK3 over NK1 and NK2 receptors (Kis = 144 and >100,000 nM, respectively, in CHO cells expressing recombinant human receptors). Talnetant inhibits calcium mobilization induced by neurokinin B in HEK293 cells expressing human NK3 receptors (IC50 = 16.6 nM). It inhibits contractions induced by the NK3 receptor agonist senktide in isolated rabbit iris sphincter muscle (pD2 = 9.1). Talnetant (5-20 mg/kg) reduces senktide-induced head shakes and tail whips in mice. It also inhibits senktide-induced wet-dog shakes, increases extracellular dopamine and norepinephrine in the medial prefrontal cortex, and attenuates haloperidol-induced increases in nucleus accumbens dopamine levels in guinea pigs. | [Uses]
Talnetant acts as a neurokinin 3 (NK3) receptor antagonist used as an antispychotic. | [in vivo]
Talnetant (SB 223412) (0.5-2 mg/kg i.v., 2 min pretreatment) can inhibit the miosis induced by senktide (25 μg, i.v.) in a dose-dependent manner with an ED50 of 0.44mg/kg in conscious rabbits[1].
Talnetant (SB 223412) (i.p., 1-100 mg/kg, 1 h) can significantly attenuate senktide-induced "wet dog wagging" behavior in a dose-dependent manner, significantly increase extracellular dopamine and norepinephrine in the medial prefrontal cortex and reduce haloperidol-induced increases in dopamine levels in the vomeronasal nucleus of freely moving guinea pigs[3].
| Animal Model: | Male Dunkin-Hartley guinea pig[3] | | Dosage: | 1, 3, 10, 30 or 100?mg/kg | | Administration: | Intraperitoneal injection; 1 h | | Result: | Showed a significant attenuation of wet dog shake (WDS) behavior from 31.1 to 16.7 at 30 mg/kg.
Significantly increased extracellular DA levels to 238% and NE levels to 227.1%, without affecting 5-HT levels.
|
| [IC 50]
NK3 | [References]
[1] H M SARAU. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.[J]. Journal of Pharmacology and Experimental Therapeutics, 1997, 281 3: 1303-1311.
[2] LEE A DAWSON. In Vitro and In Vivo Characterization of the Non-peptide NK3 Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia[J]. Neuropsychopharmacology, 2007, 33 7: 1642-1652. DOI: 10.1038/sj.npp.1301549 |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|